Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (NASDAQ:SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced strong growth in Asia Pacific, primarily fueled by growth in its Advanced Messaging business
Ardelyx Announces Acceptance Of New Drug Application For Tenapanor For Hyperphosphatemia In China; Triggers $2M Milestone Payment To Ardelyx Under The Terms Of The License Agreement Between Co And Shanghai Fosun Pharmaceutical Industrial Development C…
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that
